BMY - Bristol-Myers Squibb Company
50.91 -0.60 (-1.16%)
After hours: 7:23PM EDT
| Previous Close | 51.83 |
| Open | 51.95 |
| Bid | 51.00 x 1800 |
| Ask | 51.65 x 3100 |
| Day's Range | 51.29 - 52.07 |
| 52 Week Range | 42.48 - 59.28 |
| Volume | 8,781,675 |
| Avg. Volume | 11,374,444 |
| Market Cap | 84.259B |
| Beta (3Y Monthly) | 0.58 |
| PE Ratio (TTM) | 13.57 |
| EPS (TTM) | 3.80 |
| Earnings Date | Oct 31, 2019 |
| Forward Dividend & Yield | 1.64 (3.16%) |
| Ex-Dividend Date | 2019-07-03 |
| 1y Target Est | 60.14 |
- Zacks
Want To Retire Early? Learn the Intelligent Investing Secret - October 16, 2019
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
- GuruFocus.com
AbbVie, Bristol-Myers Squibb Getting the Most From Workers
Pharmaceutical companies that top the list in terms of sales per employee Continue reading...
- Zacks
J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion
FDA approves Johnson & Johnson's (JNJ) Xarelto to prevent blood clots in hospitalized acutely ill medical patients.
- Zacks
Bristol-Myers Squibb (BMY) Stock Moves -0.1%: What You Should Know
Bristol-Myers Squibb (BMY) closed at $51.56 in the latest trading session, marking a -0.1% move from the prior day.
- Zacks
Roche Announces Positive Late-Stage Data on Rituxan in PV
Roche (RHHBY) announces positive late-stage data on Rituxan for the treatment of moderate to severe PV.
- Zacks
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
- Zacks
Is Bristol-Myers (BMY) a Solid Growth Stock? 3 Reasons to Think " Yes "
Bristol-Myers (BMY) possesses solid growth attributes, which could help it handily outperform the market.
- GuruFocus.com
6 Stocks Trading Below Peter Lynch Value
Bristol-Myers Squibb tops the list Continue reading...
- Insider Monkey
Were Hedge Funds Right About Betting On Bristol-Myers Squibb Company (BMY)?
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees during the first half of 2019 amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a […]
- Zacks
Clovis (CLVS) Shares Drop on Goldman Sachs' Bearish Outlook
Goldman Sachs lowers price target for Clovis' (CLVS) shares taking into account the risk of lower future revenues due to rising competition in the PARP inhibitor segment.
- Zacks
Nektar's Shares Drop on Rating Downgrade by Goldman Sachs
Nektar (NKTR) continues its downfall in 2019. Goldman Sachs downgrades the company's rating from Buy to Sell.
- Market Realist
Bristol-Myers Squibb: Could BMY Stock Surge Higher?
Is Bristol-Myers Squibb stock undervalued, and could it surge higher anytime soon? Find out why further upside is possible for BMY.
- Zacks
Signs That Your Trading Will Ruin Your Retirement - October 08, 2019
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
- Zacks
Infinity's (INFI) IPI-549 in Focus in a Crowded Cancer Space
Infinity (INFI) is currently focusing on the development of its lead immuno-oncology candidate IPI-549, an orally administered treatment that selectively inhibits phosphoinositide-3 kinase (PI3K)-gamma.
- Zacks
Why Alexion is a Hot Takeover Target in the Biotech Sector
Let's take a look at the factors, which make Alexion (ALXN) a hot target for a takeover amid the M&A wave in the pharma/biotech sector.
- Business Wire
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
Bristol-Myers Squibb Company announced today the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the ...
- MoneyShow
Bristol-Myers- Value Trap of Undervalued Buy
Bristol-Myers Squibb (BMY) is best known for developing immunotherapies, biological drugs that induce a patent's immune system to attack cancerous tumors, suggests Richard Moroney, blue chip stock specialist and editor of Dow Theory Forecasts.
- Zacks
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $50.88, marking a +0.26% move from the previous day.
- Zacks
Easy Investing Secrets to an Early Retirement - October 07, 2019
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
- Zacks
Calithera (CALA) Completes Enrollment in Mid-Stage RCC Study
Calithera (CALA) completes patient enrollment in a phase II study evaluating a combination regimen of its lead candidate, telaglenastat, in patients with advanced kidney cancer.
- Investopedia
3 Drug Stocks Poised for Gains After Cancer Conference
Drug stocks have moved higher after an upbeat European cancer conference. Play three leading names using these tactical trading ideas.
- Investor's Business Daily
Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates
Pharma companies Allergan, Bristol-Myers Squibb and Zoetis could top the Street's third-quarter earnings expectations, an analyst said Thursday. But he only expects Zoetis sales to beat.
- InvestorPlace
3 Cancer-Fighting Drug Stocks to Buy Right Now
If you're looking for the top healthcare stocks to buy for the long haul, then you need to be focusing on the oncology and cancer-fighting space. The pace of innovation in the oncology sector has been truly breathtaking. Just a few years ago, many forms of cancer went untreated. However, that's not the case at all today. And new therapies are being developed all the time, making some drug stocks great investments now.For example, two different studies in Proceedings of the National Academy of Sciences (PNAS) from Rice University show the depth of new treatments. This includes targeting mitochondria as well as using gold to destroy cancer cells. With innovative approaches like those at Rice University, we're starting to win the fight against cancer.That also makes cancer-fighting firms the stocks to buy today, since all of that innovation costs a pretty penny -- with new cancer drugs being some of the most expensive on the market.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWith that in mind, the various drug stocks have either seen their products rise to blockbuster status or have the potential for future high earnings. The best part is that many of these drugs lie just beyond the reach of regulators' saber-rattling.For investors, this is another perk that makes cancer-fighting stocks truly some of the best stocks to buy for the long haul. There's plenty of potential to keep the growth and cash flows going. * 8 Stocks to Buy Offering Both Dividends and Growth But which stocks in particular stand out in the oncology space? Here are three of the best drug stocks to buy today as these companies continue in the war against cancer. Drug Stocks to Buy: Bristol-Myers Squibb (BMY)Source: Piotr Swat / Shutterstock.com If you're looking for a "sure thing" among the cancer stocks to buy, pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) could be an amazing choice. BMY has had a long history of blockbuster drugs powering its profits and dividends. And now oncology is driving that train, with blockbuster drug Opdivo leading the way.Sales for Opdivo continue to be swift. Last quarter alone, BMY managed to see a big 12% year-over-year increase in sales of the oncology medicine. Right now, Bristol-Myers pulls in nearly $2 billion in quarterly revenues from the drug alone. Even better is that the pharma continues to study how Opdivo can be used in other indications such as in esophageal cancer. This could lead to other revenue opportunities for the blockbuster.But the real reason why BMY could be a top cancer stock to buy comes down to its pending buyout of Celgene (NASDAQ:CELG). CELG comes with a rich cancer-fighting portfolio, including blockbusters Revlimid, Yervoy and Pomalyst. Adding these to BMY's umbrella creates a real powerhouse in the space. And when you combine both firms' pipelines of new drugs, you really are looking at one of the biggest cancer-fighting stocks on the planet.Meanwhile, BMY's portfolio of non-cancer drugs continues to churn out steady revenue as well. With nearly $30 billion in cash on its balance sheet and a hefty 3.24% dividend, Bristol-Meyers could be one of the best-proven winners in the oncology sector. Exact Sciences (EXAS)Source: Shutterstock In order to treat cancer, you need to detect it. And the earlier you can do that, the greater the chances of survival increase and the ability to fight it is easier. This is why Exact Sciences (NASDAQ:EXAS) could be a great pick for investors that are interested in promising drug stocks to buy.Ask anyone who has ever undergone a colonoscopy about their experience and there's a good chance they'll mention it was miserable. Because of this, colorectal cancer often goes untreated until it's too late. This makes the cancer variety the second-deadliest cancer in America. However, this is where EXAS comes in.The firm makes a diagnostic test called Cologuard, which patients can do at home via a small sample. Detection rates are nearly as good as an old-fashioned colonoscopy. This makes it a big win for both doctors and patients. And Exact Sciences has the sales growth to prove it. During its last reported quarter, EXAS managed to generate $200 million in sales from Cologuard. That was a 94% year-over-year increase in sales and a 93% jump in total test volumes.The real win is that huge jump doesn't cover the total addressable market for colorectal cancer detection nor does it include recent Food and Drug Administration wins to allow EXAS to sell Cologuard to younger age brackets.Perhaps the biggest news for EXAS could be its pending merger with rival Genomic Health (NASDAQ:GHDX). GHDX provides similar tests for the detection of breast and prostate cancer. The deal would unite two fast-growing firms under one banner. * 7 Next-Generation Healthcare Stocks to Buy For investors, that could be the ultimate win in the fight against cancer and that makes EXAS one of the top stocks to buy in the space. Bluebird Bio (BLUE)Source: Shutterstock On the surface, biotech Bluebird Bio (NASDAQ:BLUE) doesn't seem like a cancer-fighting stock. The firm is a gene-editing player whose first commercial drug -- Zynteglo -- is used in the treatment of rare blood disease, transfusion-dependent beta-thalassemia (TDT). Additionally, BLUE counts sickle cell and adrenoleukodystrophy treatments among its pipeline.But BLUE could be one of the more promising clinical-stage cancer-fighting stocks to buy. And that comes down to CAR-T. Chimeric antigen receptor T therapies use patients' own immune cells to go and attack their cancer. It's all cutting-edge stuff and Bluebird is one of the leaders. BLUE touts development deals with both Celgene and Regeneron Pharmaceuticals (NASDAQ:REGN) to use CAR-T to target multiple myeloma.So far, over the last two years, the results have been pretty impressive for lesser mentioned drug stock. Phase III trial data for its lead cancer candidate bb2121 should be released soon and BLUE and CELG estimate that approval for the medication could come in 2020. The approval should propel Bluebird to the upper echelon of drug stocks to buy. Yet, the stock has traded lower on commercial development issues related to Zynteglo.However, with more than $1.5 billion in cash, a huge potential cancer-fighting win and an overall rich pipeline, BLUE stock could be a great stock to buy for investors who are OK with taking a risk.At the time of writing, Aaron Levitt held a long position in the iShares Nasdaq Biotechnology ETF (IBB) -which holds CELG, REGN and BLUE. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Important IPO Stocks to Watch for the Long Run * 7 High Volatility Stocks to Buy as the Market Rebounds * 7 Dow Jones Industrial Average Stocks to Sell The post 3 Cancer-Fighting Drug Stocks to Buy Right Now appeared first on InvestorPlace.
- Investor's Business Daily
BMY Stock Plus Celgene Will Be A Top 5 Pharma — But Should You Buy It?
Pharmaceutical company Bristol-Myers has been in a downtrend since 2016 and after unveiling its merger with Celgene. Is now the right time to buy BMY stock?
- Reuters
Japan drug price reforms risk hurting investment -Bristol-Myers CEO
Japan's "overly restrictive" drug pricing policies risk diverting foreign direct investment to China and other markets, the chief executive of Bristol-Myers Squibb said on Thursday. The Japanese government made reforms in 2018 that change how its national health system pays for new and innovative drugs. "The world is very competitive, and countries such as China have made it a priority to develop a biopharmaceutical innovation-focused industry," Caforio said at an event organised by the Japan office of PhRMA, the main U.S. drugmaker lobby.
